ASCO与OH联合更新:无驱动基因改变IV期NSCLC系统治疗指南
推荐根据PD-L1表达水平(TPS≥50% vs 0%或1%-49%)和组织学类型(非鳞癌 vs 鳞癌)分层,优先推荐免疫单药或免疫联合化疗方案。
要点
- PD-L1高表达(TPS≥50%)非鳞癌首选帕博利珠单抗单药,可选免疫联合方案。
- PD-L1阴性或低表达非鳞癌推荐帕博利珠单抗/卡铂/培美曲塞,可选其他免疫联合或化疗。
- PD-L1高表达鳞癌首选帕博利珠单抗单药;阴性或低表达推荐帕博利珠单抗联合化疗或化疗。
核心结论
- 对于无EGFR或ALK驱动基因改变的IV期NSCLC,推荐依据PD-L1表达水平和组织学类型分层选择免疫单药或免疫联合化疗。
主要发现
- 5项随机对照试验提供了本次更新的证据基础,专家 panel 还讨论了额外文献。
关键数值与推荐
- 非鳞癌且PD-L1 TPS≥50%:推荐帕博利珠单抗单药;其他选项包括帕博利珠单抗/卡铂/培美曲塞、阿替利珠单抗/卡铂/紫杉醇/贝伐珠单抗或阿替利珠单抗/卡铂/白蛋白紫杉醇。
- 非鳞癌且PD-L1阴性(0%)或低阳性(1%-49%):推荐帕博利珠单抗/卡铂/培美曲塞;其他选项包括阿替利珠单抗/卡铂/白蛋白紫杉醇、阿替利珠单抗/卡铂/紫杉醇/贝伐珠单抗、含铂两药化疗或非铂两药方案;低阳性者可选择帕博利珠单抗单药。
- 鳞癌且PD-L1 TPS≥50%:推荐帕博利珠单抗单药;其他选项包括帕博利珠单抗/卡铂/(紫杉醇或白蛋白紫杉醇)。
- 鳞癌且PD-L1阴性(0%)或低阳性(1%-49%):推荐帕博利珠单抗/卡铂/(紫杉醇或白蛋白紫杉醇)或化疗;低阳性特定病例可选帕博利珠单抗单药。
- 推荐为条件性推荐,基于组织学、PD-L1状态和/或禁忌症存在与否。
临床怎么用
- 临床实践中应根据组织学类型和PD-L1 TPS水平分层选择一线系统治疗方案,并考虑禁忌症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver alterations. A guideline update for patients with stage IV NSCLC with driver alterations will be published separately. METHODS: The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert Panel made updated recommendations based on a systematic review of randomized controlled trials from December 2015 to 2019. RESULTS: This guideline update reflects changes in evidence since the previous guideline update. Five randomized controlled trials provide the evidence base. Additional literature suggested by the Expert Panel is discussed. RECOMMENDATIONS: Recommendations apply to patients without driver alterations in epidermal growth factor receptor or ALK. For patients with high programmed death ligand 1 (PD-L1) expression (tumor proportion score [TPS] ≥ 50%) and non-squamous cell carcinoma (non-SCC), the Expert Panel recommends single-agent pembrolizumab. Additional treatment options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel. For most patients with non-SCC and either negative (0%) or low positive (1% to 49%) PD-L1, the Expert Panel recommends pembrolizumab/carboplatin/pemetrexed. Additional options are atezolizumab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/bevacizumab, platinum-based two-drug combination chemotherapy, or non-platinum-based two-drug therapy. Single-agent pembrolizumab is an option for low positive PD-L1. For patients with high PD-L1 expression (TPS ≥ 50%) and SCC, the Expert Panel recommends single-agent pembrolizumab. An additional treatment option is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel). For most patients with SCC and either negative (0%) or low positive PD-L1 (TPS 1% to 49%), the Expert Panel recommends pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemotherapy. Single-agent pembrolizumab is an option in select cases of low positive PD-L1. Recommendations are conditional on the basis of histology, PD-L1 status, and/or the presence or absence of contraindications. Additional information is available at www.asco.org/lung-cancer-guidelines.
引用
- Hanna NH, Schneider BJ, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2020. PMID: 31990617. doi:10.1200/JCO.19.03022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。